Wedbush reiterates Outperform rating on Arcus Biosciences, $43 price target

Wedbush reiterated their Outperform rating on Arcus Biosciences's stock with a price target of $43.00.The price target implies an upside of 67.6% from the Sep 29 close of $25.65.Key takeaways from the analyst notePositive Product Pipeline: Arcus Biosciences is advancing a robust pipeline of therapi…